Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August
U.S. stocks mixed as Dow and S&P fell despite strong August job gains; tech rose, energy slid, and oil, gold and silver declined.
Stocks · News reference
BioXcel Therapeutics Announced That It Has Entered Into An Asset Sale Agreement With Teva Pharmaceuticals International For Substantially All Of The Company’s Assets
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Samsara Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Samsara jumped 14.8% premarket after Q2 results beat estimates; several stocks surged, while DSS plunged 36.4% on a proposed offering.
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Snowflake shares surged 24% after Q2 revenue and earnings beat estimates; other premarket gainers and losers made notable moves.
8-K filing — BioXcel Therapeutics, Inc. (BTAI)
Filed: 2026-09-01 AccNo: 0001104659-26-104106 Size: 205 KB Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
UBS Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $48
UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $42 to $48.
Teva Reports Significant Prevention Of Gluten-Induced Damage in New Study
Teva reports positive Phase 2a results for TEV '408, successfully preventing gluten-induced intestinal damage in adult celiac patients.